source
- Mirador unveils part of pipeline with drug from Kira to rival TavneosMirador Therapeutics, the secretive immune disease biotech with more than $650 million in VC funding, is finally revealing a piece of its pipeline. The San Diego biotech said Thursday it reached a…Endpoints · 26d ago↗ source
- What health system execs are talking aboutEarlier this week, I swung by the American Hospital Association’s Leadership Summit in downtown Denver. When I wasn’t giving out ice cream recommendations, I was trying to get a sense of what hospi…Endpoints · 27d ago↗ source
- Kelun pads efficacy profile of Merck-partnered ADC; Europe will have to wait for Boehringer's HernexeosPlus, news about Vogenx and Orakl Oncology. 🇨🇳 Kelun touts China data for sac-TMT: Kelun-Biotech announced on Tuesday that its Merck-partnered antibody-drug conjugate sacituzumab tirumotecan succ…